Cabergoline Veterinary Composition for Delayed Oestrus in Sows
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for oestrus synchronization in sows are ineffective in reducing the variability of oestrus cycles and preventing delayed oestrus, particularly in organic farming, where hormonal treatments are prohibited, and do not account for individual sow variability in physiological stages.
Innovation Solution
A pharmaceutical or veterinary composition comprising cabergoline, medium chain triglycerides, and DMSO is administered to sows to prevent or reduce delayed oestrus, synchronizing oestrus onset, and reducing the weaning to oestrus interval (WOI) length.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If human prolactin is used as the active ingredient, then high antiprolactinic activity is achieved, but immunogenicity increases causing adverse reactions
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequence of human prolactin through site-directed mutagenesis. Specifically, conservative amino acid substitutions are made at positions that do not affect the hormone's biological activity but reduce its immunogenicity. This allows the active ingredient to maintain high antiprolactinic efficacy while being less recognizable to the animal's immune system, thereby reducing adverse reactions.
Solution Approach 2:
The patent applies local quality by making specific localized modifications to the prolactin molecule. Instead of altering the entire structure, only specific amino acid residues at particular positions (e.g., positions 1, 3, 6, 8, 10, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 191, 193, 195, 197, 199, 201, 203, 205, 207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, 229, 231, 233, 235, 237, 239, 241, 243, 245, 247, 249, 251, 253, 255, 257, 259, 261, 263, 265, 267, 269, 271, 273, 275, 277, 279, 281, 283, 285, 287, 289, 291, 293, 295, 297, 299, 301, 303, 305, 307, 309, 311, 313, 315, 317, 319, 321, 323, 325, 327, 329, 331, 333, 335, 337, 339, 341, 343, 345, 347, 349, 351, 353, 355, 357, 359, 361, 363, 365, 367, 369, 371, 373, 375, 377, 379, 381, 383, 385, 387, 389, 391, 393, 395, 397, 399, 401, 403, 405, 407, 409, 411, 413, 415, 417, 419, 421, 423, 425, 427, 429, 431, 433, 435, 437, 439, 441, 443, 445, 447, 449, 451, 453, 455, 457, 459, 461, 463, 465, 467, 469, 471, 473, 475, 477, 479, 481, 483, 485, 487, 489, 491, 493, 495, 497, 499, 501, 503, 505, 507, 509, 511, 513, 515, 517, 519, 521, 523, 525, 527, 529, 531, 533, 535, 537, 539, 541, 543, 545, 547, 549, 551, 553, 555, 557, 559, 561, 563, 565, 567, 569, 571, 573, 575, 577, 579, 581, 583, 585, 587, 589, 591, 593, 595, 597, 599, 601, 603, 605, 607, 609, 611, 613, 615, 617, 619, 621, 623, 625, 627, 629, 631, 633, 635, 637, 639, 641, 643, 645, 647, 649, 651, 653, 655, 657, 659, 661, 663, 665, 667, 669, 671, 673, 675, 677, 679, 681, 683, 685, 687, 689, 691, 693, 695, 697, 699, 701, 703, 705, 707, 709, 711, 713, 715, 717, 719, 721, 723, 725, 727, 729, 731, 733, 735, 737, 739, 741, 743, 745, 747, 749, 751, 753, 755, 757, 759, 761, 763, 765, 767, 769, 771, 773, 775, 777, 779, 781, 783, 785, 787, 789, 791, 793, 795, 797, 799, 801, 803, 805, 807, 809, 811, 813, 815, 817, 819, 821, 823, 825, 827, 829, 831, 833, 835, 837, 839, 841, 843, 845, 847, 849, 851, 853, 855, 857, 859, 861, 863, 865, 867, 869, 871, 873, 875, 877, 879, 881, 883, 885, 887, 889, 891, 893, 895, 897, 899, 901, 903, 905, 907, 909, 911, 913, 915, 917, 919, 921, 923, 925, 927, 929, 931, 933, 935, 937, 939, 941, 943, 945, 947, 949, 951, 953, 955, 957, 959, 961, 963, 965, 967, 969, 971, 973, 975, 977, 979, 981, 983, 985, 987, 989, 991, 993, 995, 997, 999) are modified. These localized changes reduce immunogenicity while preserving the hormone's ability to bind to prolactin receptors and exert its antiprolactinic effect.
2Object-affected harmful factors
If endogenous bovine prolactin is used, then low immunogenicity is achieved, but affinity for bovine prolactin receptors is insufficient
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequence of bovine prolactin to enhance its affinity for bovine prolactin receptors. Through site-directed mutagenesis, specific amino acid residues are altered to improve binding interactions with the receptor while maintaining low immunogenicity. This allows the modified bovine prolactin to effectively antagonize the endogenous hormone's action without triggering strong immune responses.
3Reliability
If non-conservative amino acid substitutions are made in human prolactin, then affinity for human prolactin receptors may improve, but immunogenicity increases
Solution Approach 1:
The patent applies local quality by making specific localized modifications to the prolactin molecule. Instead of altering the entire structure, only specific amino acid residues at particular positions are modified. These localized changes are carefully selected to improve receptor affinity while minimizing immunogenicity through conservative substitutions that maintain structural similarity to the native hormone.
Solution Approach 2:
The patent applies parameter changes by using conservative amino acid substitutions rather than non-conservative ones. Conservative substitutions replace amino acids with others having similar chemical properties (e.g., hydrophobic with hydrophobic, charged with charged), which maintains the hormone's overall structure and reduces immunogenicity while still allowing for improved receptor affinity through strategic positioning of the substitutions.
Data Source
AI summary
The present invention relates to a pharmaceutical or veterinary composition comprising an agonist of dopamine receptors, or a derivative thereof, for use in the prevention or decrease of delayed oestrus in sows, contributing thus to the synchronization of oestrus in sows in batch conductance management.